LSCP Laserscope (MM)

SAN JOSE, Calif., Jan. 10 /PRNewswire-FirstCall/ -- Laserscope (NASDAQ:LSCP), a pioneer in the development and commercialization of minimally-invasive medical devices, including medical lasers and advanced fiber-optic delivery devices, today announced the positive results of the first prospective study comparing Photoselective Vaporization of the Prostate (PVP) performed with the Company's GreenLight PV(R) laser system with the more traditional Transurethral Resection of the Prostate (TURP) for the treatment of obstructive Benign Prostatic Hyperplasia (BPH). Investigators from the University of Basel and from Cantons Spital Baden in Switzerland reported their findings in the December issue of the European Urology journal. The authors of the study, which included data from 101 patients, found that "PVP provides excellent intraoperative safety, instant tissue removal, and immediate relief from obstructive voiding symptoms, similar to TURP." Dr. Alexander Bachmann, the study's lead investigator, commented that, "PVP has become the standard of care at the University of Basel." Professor Tullio Sulser, Head of the Urology Department at the University of Basel, and senior author of the study added that, "The GreenLight PV(R) laser system has proven to be an extremely effective tool in our long-term experience of more then three years." The authors also noted that PVP has the potential to reduce health care expenses for the treatment of obstructive BPH. "Although capital investment for the laser generator and disposable costs for the single-use laser fiber are significant, cost savings for insurers become evident once the shorter hospital stay, lower incidence and reduced severity of post-operative complications for PVP compared to TURP are taken into consideration." "We are very excited to see published evidence of the significant advantages our GreenLight PV(R) laser system offers over TURP, which has been the 'Gold Standard' for the treatment of BPH over the last several decades," said Eric Reuter, President and Chief Executive Officer of Laserscope. "Although long-term, follow-up of comparison trials are still needed to confirm the initial positive results of this study, we are convinced that PVP is becoming the new de-facto standard of care given the growing number of consistently positive reports from educational and medical centers around the world." About Laserscope Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of minimally-invasive medical products including medical laser systems and related energy delivery devices for the office, outpatient surgical center, and hospital markets. More information about Laserscope can be found on the Company's web site at http://www.laserscope.com/. Safe Harbor Statement This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by this section. These forward-looking statements include statements about the efficiency of Laserscope's PVP procedure compared to transurethral resection of the prostate in treating Benign Prostatic Hyperplasia. These statements are subject to a number of risks and uncertainties, including among others: uncertainties regarding introduction of new technologies competitive to Laserscope's products and the degree to which the Company's current and new products are accepted by customers, which could affect the level of demand for our products; uncertainties regarding our ability to compete with companies that have significantly greater financial, technical, research and development, manufacturing and marketing resources than we have; and uncertainties that new products will receive regulatory approval in applicable jurisdictions. Actual results may differ materially due to these and other factors. The matters discussed in this press release also involve risks and uncertainties described from time to time in Laserscope's filings with the Securities and Exchange Commission. In particular, see the Risk Factors described in Laserscope's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Copies of Laserscope's public disclosure filings with the SEC, including the most recent Annual Report on Form 10-K and the most recent forms 10-Q are available upon request from its Investor Relations Department at its website at http://www.laserscope.com/ and at the SEC's website: http://www.sec.gov/. Laserscope assumes no obligation to update the forward-looking information contained in this press release. At Laserscope: At Financial Relations Board: Eric Reuter, President & CEO Tricia Ross, Investor/Analyst Contact Derek Bertocci, CFO (617) 520-7064 (408) 943-0636 Laurie Berman, General Inquiries (310) 854-8315 DATASOURCE: Laserscope CONTACT: Eric Reuter, President & CEO, or Derek Bertocci, CFO, both of Laserscope, +1-408-943-0636; or Investor/Analyst Contact, Tricia Ross, +1-617-520-7064, or General Inquiries, Laurie Berman, +1-310-854-8315, both of Financial Relations Board for Laserscope Web site: http://www.laserscope.com/

Copyright